IFN-γ/IL-27 axis induces PD-L1 expression in monocyte-derived dendritic cells and restores immune tolerance in CNS autoimmunity by Vattikonda, Asrita et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Phase 1 Class of 2023 
2-2021 
IFN-γ/IL-27 axis induces PD-L1 expression in monocyte-derived 






Hélène C. Descamps 
See next page for additional authors 
Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2023_phase1 
 Part of the Translational Medical Research Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more 
information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Authors 
Asrita Vattikonda, Giacomo Casella, Javad Rasouli, Rodolfo Thome, Hélène C. Descamps, Larissa 
Ishikawa, Alexandra Boehm, Daniel Hwang, Weifeng Zhang, Dan Xiao, Jeongho Park, Guang-Xian Zhang, 
Jorge I. Alvarez, Abdolmohamad Rostami, and Bogoljub Ciric 
IFN-γ/IL-27 axis induces PD-L1 expression in 
monocyte-derived dendritic cells and 
restores immune tolerance in CNS 
autoimmunity
Asrita Vattikonda, Giacomo Casella, Javad Rasouli, Rodolfo Thome, Hélène C. 
Descamps, Larissa Ishikawa, Alexandra Boehm, Daniel Hwang, Weifeng Zhang, Dan 
Xiao, Jeongho Park, Guang-Xian Zhang, Jorge I Alvarez, Abdolmohamad Rostami*, 
and Bogoljub Ciric
(*) indicates primary project advisor
(**) indicates another student who is declaring the same project as primary for SI
Introduction: 
Clinical Significance
• Multiple sclerosis (MS) is an autoimmune disease of the CNS 
involving inflammation and demyelination
• Presents with varying debilitating symptoms including 
fatigue, pain, tremor, and paralysis
• Affects over 100 per 100,000 people in North America
Introduction:
Background
• Therapies based on restoring Ag-specific immune tolerance 
induction have been a long-standing goal for treatment of 
autoimmune diseases
• Advantage of Ag-specific therapy 
– Selective suppression of a pathogenic immune response
– Not impairing systemic immunity → avoid adverse effects of 
immunosuppression
• Previous studies of auto-Ag IV tolerance induction 
– Extensively studied in experimental autoimmune encephalomyelitis 
(EAE), an animal model of MS
– Limited clinical trials demonstrated that it is safe and beneficial to a 
subset of MS patients
• Mechanisms of IV tolerance induction are incompletely 
understood, which limits the development of better approaches 




– How does the IFN-γ/IL-27/PD-L1 axis affect mice 
with an animal model of multiple sclerosis?
• Hypothesis
– In mice with an animal model of multiple 
sclerosis, the IFN-γ/IL-27/PD-L1 axis leads to 
apoptosis of pathogenic CD4+ T cells, resulting 
in amelioration of disease.
Approach & Results
• Experimental protocols using mice (n=10/group
per experiment) were approved by IACUC of TJU
• EAE
– Injection of MOG peptide, heat-killed 
Mycobacterium tuberculosis, pertussis toxin
– Daily clinical assessment 
• PD-L1, PD-L2, IFN-γ blockade via MAb injection
• IV Tolerance Induction after onset of clinical 
disease
– Injections of MOG every third day, three times
– Control mice received vehicle only
• Isolation of cells from spleen and CNS
• Analysis techniques: flow cytometry, ELISA, qPCR
Approach & Results
Intravenous Tolerance Induction in EAE Is 
Dependent on Programmed Death Ligand 1 
(PD-L1)
Analyses between two groups were carried out by Student’s t-test and between four groups by one-way ANOVA with 
Bonferroni post-test. EAE experiments were analyzed by two-way ANOVA with Bonferroni’s multiple comparison. Values 
of ** P < 0.001, *** P < 0.0001, and **** P < 0.00001 were considered significant.
Approach & Results
Interferon-γ Secreted by CD4+ T Cells Is 
Necessary for EAE Suppression Upon MOG/IV 
Treatment
Analyses between two groups were carried out by Student’s t-test and between four groups by one-way ANOVA with 
Bonferroni post-test. EAE experiments were analyzed by two-way ANOVA with Bonferroni’s multiple comparison. Values 
of ** P < 0.001, *** P < 0.0001, and **** P < 0.00001 were considered significant.
Approach & Results
Interleukin-27 Induces PD-L1 Expression in 
Monocyte-Derived Dendritic Cells and 
Improves Disease Outcomes
Analyses between two groups were carried out by Student’s t-test and between four groups by one-way ANOVA with 
Bonferroni post-test. EAE experiments were analyzed by two-way ANOVA with Bonferroni’s multiple comparison. Values 
of ** P < 0.001, *** P < 0.0001, and **** P < 0.00001 were considered significant.
Conclusions
• IV Auto-Ag injected into mice with clinical EAE 
→ IFN-γ → IL-27 → PD-L1 → apoptosis/anergy 
of pathogenic CD4+ T cells → disease 
amelioration 
• Depletion of autoreactive is a well-known 
mechanism of tolerance, but our study defines a 
pathway between molecular and cellular factors 
that leads to this development 
• Sheds light on this signaling axis and the use of 
immune tolerance as a potential therapeutic in 
people with MS
Future Directions
• Additional molecules may be involved in this 
pathway, such as IL-10
• Upregulation of TGF-β has also been noted, 
but its significance has not been explored
• This regulatory pathway is relevant in other 
contexts
• Explore use of immune tolerance in other 
autoimmune diseases
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